

### **Aspira Pathlab & Diagnostics Limited**

(Formerly known as Utkal Soap Products Ltd.)

**Regd. Office:** Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086

CIN:L85100MH1973PLC289209

Corporate Office: Plot No. 6, RPT House, Sector 24, Turbhe, Navi Mumbai 400 703

January 30, 2019

The Department of Corporate services, BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400 001

Scrip Code: 540788

Subject: Newspaper advertisement pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Dear Sir,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, we are enclosing herewith the copy of Newspaper advertisement of the Standalone Audited Financial Results for the quarter ended 31<sup>st</sup> December, 2018 published in Business Standard (English Language) and Lakshadeep (Marathi Language) on January 22, 2019 for your reference and record.

Kindly take the note of the same.

Thanking you.

Yours faithfully,

For Aspira Pathlab & Diagnostics Limited

Mamta Mav

Company Secretary

Encl: as above

## Business Standard MUMBAI | TUESDAY, 22 JANUARY 2019

## PASPIRA"

#### **ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

CIN: - L85100MH1973PLC289209

Reg. Office: Flat No.2, R.D.Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W.), Mumbai -400086

Corporate office: Plot no.6, RPT House, Sector 24, Turbhe, Navi Mumbai - 400705

Tel No.: 71975656; email ID: info@aspiradiagnostics.com; website: www.aspiradiagnostics.com

Extracts of unaudited Financial Results for the Quarter Ended December 31, 2018

(Rupees in Lakhs)

Sr. No	Particulars Particulars	Quarter Ended 31/12/2018 (Unaudited)	Previous year ended 31/03/2018 (Audited)	Quarter ended 31/12/2017 (Unaudited)
1.	Total income from operations	208.06	435.78	126.15
2.	Net Profit / (Loss) for the period (before Tax, Exceptional	bile imenu	redice, the	mor ia
	and /or Extraordinary items#)	(123.24)	(558.23)	(134.37)
3.	Net Profit / (Loss) for the period before tax			Section 5
	(after Exceptional and/or Extraordinary items#)	(123.24)	(558.23)	(134.37)
4.	Net Profit / (Loss) for the period after tax			
	(after Exceptional and/or Extraordinary items#)	(123.24)	(558.23)	(134.37)
5.	Total Comprehensive Income for the period	<b>可以及其一</b>		
	(Comprising profit/(loss) for the period(after tax) and	10		
1	other Comprehensive Income(after tax)	(123.24)	(558.23)	(134.37)
6.	Equity Share Capital	819.30	519.30	519.30
7.	Reserves (excluding Revaluation Reserve) as shown			N. September 1
otel	in the Audited Balance Sheet of previous year)	-		1
8.	Earnings Per Share (of ₹ 10/- each)		3604	
	(for continuing and discontinued operations)-		HEVIEW	2008 w
900	Basic:	(1.50)	(10.75)	(2.59)
med	Diluted:	(1.50)	(10.75)	(2.59)

#### Note

- a. The above is an extract of the detailed format of Unaudited Financial Results for the Quarter ended December 31, 2018, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Year ended 31st March 2018 is available on the websites of the Stock Exchange(s) and the company's website: - www.aspiradiagnostics.com.
- The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on January 21st, 2019.

For and on behalf of the Board For Aspira Pathlab & Diagnostics Limited

Place: - Mumbai Date: - January 21, 2019 Sd/-Mamta May Company Secretary

## मंगळवार, दि. २२ जानेवारी २०१९

# मुंबई लक्षदीप



## POASPIRA"

#### **ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

CIN: - L85100MH1973PLC289209

Reg. Office : Flat No.2, R.D.Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W.), Mumbai -400086

Corporate office: Plot no.6, RPT House, Sector 24, Turbhe, Navi Mumbai - 400705

Tel No.: 71975656; email ID: <a href="mailto:info@aspiradiagnostics.com">info@aspiradiagnostics.com</a>; website: www.aspiradiagnostics.com

Extracts of unaudited Financial Results for the Quarter Ended December 31, 2018

(Rupees in Lakhs)

Sr. No	Particulars Particulars	Quarter Ended 31/12/2018 (Unaudited)	Previous year ended 31/03/2018 (Audited)	Quarter ended 31/12/2017 (Unaudited)
1.	Total income from operations	208.06	435.78	126.15
2.	Net Profit / (Loss) for the period (before Tax, Exceptional	core no ac		diffe. 6
TEST	and /or Extraordinary items#)	(123.24)	(558.23)	(134.37)
3.	Net Profit / (Loss) for the period before tax	व्यवापसाम्बक		alt libibite
T P	(after Exceptional and/or Extraordinary items#)	(123.24)	(558.23)	(134.37)
4.	Net Profit / (Loss) for the period after tax	वास्तानाहा		कुनमण्ड .
or en	(after Exceptional and/or Extraordinary items#)	(123.24)	(558.23)	(134.37)
5.	Total Comprehensive Income for the period	पहले होते		STHE SHIP
	(Comprising profit/(loss) for the period(after tax) and	विवादार		SHOOM SELECTION
	other Comprehensive Income(after tax)	(123.24)	(558.23)	(134.37)
6.	Equity Share Capital	819.30	519.30	519.30
7.	Reserves (excluding Revaluation Reserve) as shown			
3	in the Audited Balance Sheet of previous year)	DICH	HOLLE	117.7
8.	Earnings Per Share (of ₹ 10/- each)	A A A A A		
	(for continuing and discontinued operations)-	FAM WEET	ex Foro) \$	178 ME
41	Basic: Park Company Park Company	(1.50)	(10.75)	(2.59)
OTHER.	Diluted:	(1.50)	(10.75)	(2.59)

#### Note:

a. The above is an extract of the detailed format of Unaudited Financial Results for the Quarter ended December 31, 2018, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Year ended 31st March 2018 is available on the websites of the Stock Exchange(s) and the company's website: - www.aspiradiagnostics.com.

 The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on January 21st, 2019.

For and on behalf of the Board For Aspira Pathlab & Diagnostics Limited Sd/-

Place: - Mumbai

Date: - January 21, 2019

Mamta Mav Company Secretary